secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109718
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter
--------------------------------------------------------------------------------

- Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.
- Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.
- Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.
- Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.
- Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/0001104659-25-109718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer